Identification of SARS-CoV-2-specific T cell and its receptor
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: AI-supported repertoire analysis is linked to specific SARS-CoV-2 T-cell/TCR identification that is experimentally followed up. Specificity and cytotoxicity evidence is in defined assays/animal models, not clinical efficacy.
Technology: ML classifier based on TCR sequence features distinguishes COVID patients and healthy controls (95.7% accuracy); peptide stimulation in HLA-A*02 vaccinated individuals identifies SARS-CoV-2-specific T cells/TCRs, with cloned TCR functional assays and mouse intranasal peptide immunization showing T-cell responses. Findings include specific TCR/epitope response. Distinguish human ex-vivo, in-vitro and mouse evidence; no human vaccine efficacy claim
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- ML classifier based on TCR sequence features distinguishes COVID patients and healthy controls (95.7% accuracy); peptide stimulation in HLA-A*02 vaccinated individuals identifies SARS-CoV-2-specific T cells/TCRs, with cloned TCR functional assays and mouse intranasal peptide immunization showing T-cell responses. Findings include specific TCR/epitope response. Distinguish human ex-vivo, in-vitro and mouse evidence; no human vaccine efficacy claim
- Limitation / still unknown
- The result is limited to the reported dataset, experimental setting and validation in this study; broader generalization and real-world benefit are not established.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://link.springer.com/article/10.1186/s13045-024-01537-6
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.